Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

Virginia M. Klimek, Emily K. Dolezal, Larry Smith, Gerald Soff, Stephen D Nimer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.

Original languageEnglish
Pages (from-to)570-574
Number of pages5
JournalLeukemia Research
Volume36
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Sodium Salicylate
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Salicylates
Transaminases
Anti-Inflammatory Agents
Drug Therapy
Liver
In Vitro Techniques

Keywords

  • Acute myelogenous leukemia
  • Myelodysplastic syndromes
  • NF-κB
  • Sodium salicylate

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. / Klimek, Virginia M.; Dolezal, Emily K.; Smith, Larry; Soff, Gerald; Nimer, Stephen D.

In: Leukemia Research, Vol. 36, No. 5, 01.05.2012, p. 570-574.

Research output: Contribution to journalArticle

Klimek, Virginia M. ; Dolezal, Emily K. ; Smith, Larry ; Soff, Gerald ; Nimer, Stephen D. / Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. In: Leukemia Research. 2012 ; Vol. 36, No. 5. pp. 570-574.
@article{068675e083354dc0a9e60371cd05f83d,
title = "Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia",
abstract = "Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.",
keywords = "Acute myelogenous leukemia, Myelodysplastic syndromes, NF-κB, Sodium salicylate",
author = "Klimek, {Virginia M.} and Dolezal, {Emily K.} and Larry Smith and Gerald Soff and Nimer, {Stephen D}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.leukres.2011.10.023",
language = "English",
volume = "36",
pages = "570--574",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

AU - Klimek, Virginia M.

AU - Dolezal, Emily K.

AU - Smith, Larry

AU - Soff, Gerald

AU - Nimer, Stephen D

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.

AB - Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.

KW - Acute myelogenous leukemia

KW - Myelodysplastic syndromes

KW - NF-κB

KW - Sodium salicylate

UR - http://www.scopus.com/inward/record.url?scp=84858751230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858751230&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.10.023

DO - 10.1016/j.leukres.2011.10.023

M3 - Article

C2 - 22154022

AN - SCOPUS:84858751230

VL - 36

SP - 570

EP - 574

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -